Literature DB >> 20843947

Increased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegaly.

Jitske Tiemensma1, Nienke R Biermasz, Roos C van der Mast, Moniek J E Wassenaar, Huub A M Middelkoop, Alberto M Pereira, Johannes A Romijn.   

Abstract

OBJECTIVE: Active acromegaly is associated with psychopathology, personality changes, and cognitive dysfunction. It is unknown whether, and to what extent, these effects are present after long-term cure of acromegaly. AIM: The aim of the study was to assess psychopathology, personality traits, and cognitive function in patients after long-term cure of acromegaly.
DESIGN: This was a cross-sectional study. PATIENTS AND METHODS: We studied 68 patients after long-term cure (13±1 yr) of acromegaly and 68 matched controls. We compared these data with 60 patients treated for nonfunctioning pituitary macroadenomas (NFMAs) and 60 matched controls. Psychopathology was assessed using the Apathy Scale, Irritability Scale, Hospital Anxiety and Depression Scale, and Mood and Anxiety Symptoms Questionnaire short-form, and personality was assessed by the Dimensional Assessment of Personality Pathology short-form (DAPPs). Cognitive function was assessed by 11 tests.
RESULTS: Compared with matched controls, patients cured from acromegaly scored significantly worse on virtually all psychopathology questionnaires and on several subscales of the DAPPs. Compared with NFMA patients, patients cured from acromegaly scored worse on negative affect (P=0.050) and somatic arousal (P=0.009) and seven of 18 subscales of the DAPPs (P<0.05). Cognitive function in patients cured from acromegaly did not differ from matched controls or patients treated for NFMA.
CONCLUSION: Patients with long-term cure of acromegaly show a higher prevalence of psychopathology and maladaptive personality traits but not cognitive dysfunction, compared with matched controls and patients treated for NFMA. These results suggest irreversible effects of previous GH excess, rather than effects of pituitary adenomas per se and/or their treatment, on the central nervous system.

Entities:  

Mesh:

Year:  2010        PMID: 20843947     DOI: 10.1210/jc.2010-1253

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Neuropsychological functioning in acromegaly: towards identification of modifiable factors to improve long-term care after remission.

Authors:  Alberto M Pereira
Journal:  Endocrine       Date:  2015-09-08       Impact factor: 3.633

2.  Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL.

Authors:  Cornelie D Andela; Nicolasine D Niemeijer; Margreet Scharloo; Jitske Tiemensma; Shaaji Kanagasabapathy; Alberto M Pereira; Noëlle G A Kamminga; Ad A Kaptein; Nienke R Biermasz
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

3.  Evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy.

Authors:  H Alibas; K Uluc; P Kahraman Koytak; M M Uygur; N Tuncer; T Tanridag; D Gogas Yavuz
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

4.  Perception of health and cognitive dysfunction in acromegaly patients.

Authors:  Iris Crespo; Susan M Webb
Journal:  Endocrine       Date:  2014-03-25       Impact factor: 3.633

5.  Neurocognitive long-term impact of two-field conventional radiotherapy in adult patients with operated pituitary adenomas.

Authors:  Beatriz Lecumberri; Javier Estrada; José García-Uría; Isabel Millán; Luis Felipe Pallardo; Luis Caballero; Tomás Lucas
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

6.  The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system.

Authors:  Serdar Sahin; Tevhide Betul Icli; Emre Durcan; Cem Sulu; Hande Mefkure Ozkaya; Ali Ibrahim Hatemi; Pinar Kadioglu
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

7.  Paternal deprivation prior to adolescence and vulnerability to pituitary adenomas.

Authors:  L G Sobrinho; J S Duarte; I Paiva; L Gomes; V Vicente; P Aguiar
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

8.  Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study.

Authors:  Chris G Yedinak; Maria Fleseriu
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

9.  Quality of life in female patients with acromegaly.

Authors:  O Celik; P Kadioglu
Journal:  J Endocrinol Invest       Date:  2012-11-26       Impact factor: 4.256

10.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.